Communiqués Syros Pharmaceuticals, Inc. Börse Stuttgart

Actions

0S90

US87184Q2066

Recherche biotechnologique et médicale

Marché Fermé - Börse Stuttgart Autres places de cotation 13:23:47 19/03/2025			Varia. 5j.	Varia. 1 janv.
0,1140 ^EUR	-12,31%		+42,50%	-41,84%

28/02/25	Syros Pharmaceuticals se retire du Nasdaq et désenregistre ses actions ordinaires	MT
28/02/25	Syros Pharmaceuticals, Inc. annonce la cessation des fonctions de Gerald Quirk en tant que directeur général, à compter du 1er mars 2025	CI

Communiqués

28/02/25	Syros Announces Voluntary Delisting from Nasdaq and SEC Deregistration	BU
18/11/24	Syros Pharmaceuticals : Management Change/Compensation Form 8 K	PU
13/11/24	Syros Pharmaceuticals : Announces Topline Data from SELECT MDS 1 Phase 3 Trial of Tamibarotene in Higher Risk Myelodysplastic Syndrome with RARA Gene Overexpression Form 8 K	PU
12/11/24	Syros Announces Topline Data from SELECT-MDS-1 Phase 3 Trial of Tamibarotene in Higher-Risk Myelodysplastic Syndrome with RARA Gene Overexpression	BU
01/11/24	Syros Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides a Business Update	AQ
31/10/24	Syros Pharmaceuticals : Release Q3 2024	PU
31/10/24	Syros Reports Third Quarter 2024 Financial Results and Provides a Business Update	BU
24/10/24	Syros to Report Third Quarter 2024 Financial Results on Thursday, October 31, 2024	BU
27/08/24	Syros Pharmaceuticals to Present at Upcoming Medical and Investor Conferences	BU
12/08/24	Syros Provides Update on SELECT-AML-1 Phase 2 Clinical Trial	BU
31/07/24	Syros Reports Second Quarter 2024 Financial Results and Provides a Business Update	BU
24/07/24	Syros to Report Second Quarter 2024 Financial Results on Wednesday, July 31, 2024	BU
13/06/24	Syros to Host Webcast Event on Higher-Risk Myelodysplastic Syndrome and the Opportunity for Tamibarotene to Become the New Frontline Standard-of-Care for Patients with RARA Gene Overexpression	BU
14/05/24	Syros Reports First Quarter 2024 Financial Results and Provides a Corporate Update	BU
07/05/24	Syros to Participate in Upcoming Investor Conferences	BU
07/05/24	Syros to Report First Quarter 2024 Financial Results on Tuesday, May 14, 2024	BU
09/04/24	Syros Receives Fast Track Designation from the FDA for Tamibarotene for the Treatment of Newly Diagnosed Unfit AML with RARA gene overexpression	BU
03/04/24	Syros Reports Inducement Grants under Nasdaq Listing Rule 5635(4)	AQ
02/04/24	Syros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	BU
27/03/24	Syros Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Corporate Update	BU
25/03/24	Syros Announces Completion of Enrollment of 190 Patients Necessary to Support Primary Endpoint Analysis in SELECT-MDS-1 Phase 3 Trial	BU
20/03/24	Syros to Report Fourth Quarter and Full Year 2023 Financial Results on Wednesday, March 27, 2024	BU
27/02/24	Syros to Participate in TD Cowen 44th Annual Health Care Conference	BU
08/01/24	Syros Highlights Anticipated 2024 Milestones to Deliver on the Value of Tamibarotene	BU
19/12/23	Syros Announces Pricing of $45.0 million Underwritten Offering of Common Stock and Pre-Funded Warrants	BU